Gabrić je zakon ! Leonardo Bressan, dr. med. Dana 13. 8. 2012. 20:23 "aleksandar ljubotina" < alexandar_ljubotina@xxxxxxxxx> je napisao/la: > Veceras u 20.35 na HRT1 "U krupnom planu": Afera Pfizer, ne bi bilo loše > pogledati![image: :-h wave] > > *From:* Dr. Jadranka Okmazic < > okmazic.jadrankaord.opce.medicine@xxxxxxxxxxx> > *To:* smartdoctor@xxxxxxxxxxxxx > *Sent:* Friday, August 10, 2012 5:41 PM > *Subject:* [smartdoctor] Fw: Re: Afera Pfizer > ** > > > ----- Original Message ----- > *From:* aleksandar ljubotina <alexandar_ljubotina@xxxxxxxxx> > *To:* smartdoctor@xxxxxxxxxxxxx > *Sent:* Friday, August 10, 2012 12:08 PM > *Subject:* [smartdoctor] Re: Afera Pfizer > > Hvala ti Jadranka, problem je što javna gladila ne glade SLOM-ove, nego > neke druge socijalne skupine u RH...ali vrijedi se boriti [image: :-h > wave]- > > *From:* J Soic <jsoic@xxxxxxxxx> > *To:* Listaaa <smartdoctor@xxxxxxxxxxxxx> > *Sent:* Friday, August 10, 2012 11:24 AM > *Subject:* [smartdoctor] Re: Afera Pfizer > Ovaj bih mail objavila u javnim gladilima u ime svih obiteljskih > lijecnika.** > Sent from Yahoo! Mail on Android > *From: *aleksandar ljubotina <alexandar_ljubotina@xxxxxxxxx>; > *To: *smartdoctor@xxxxxxxxxxxxx <smartdoctor@xxxxxxxxxxxxx>; > *Subject: *[smartdoctor] Re: Afera Pfizer > *Sent: *Fri, Aug 10, 2012 7:56:42 AM > Dragi svi, > nekako mi se čini da je farmaceutska tvrtka s dva nježna ženska imena u > nazivu nadmašila Pfizer, barem u RH: Forteo, Byetta, Zypadhera...uvjeren > sam da ti lijekovi nisu osvanuli na listi HZZO-a posredovanjem i zaslugom > obiteljskih liječnika. > > Molim da uočite da smo napokon izjednačeni s uglednim profesorima iz > različitih odbora za lijekove i predstojnicima klinika,ako već ne po > stručnosti, onda po koruptivnom potencijalu.. Naglasak je na potencijalu, > jer sumnjam da bilo tko od nas ima inozemne bankovne račune u koje redovito > mjesečno kapne koja tisućica eura, i pun salon trofeja s afričkih safarija. > Ako uzmemo da prosječni SLOM propiše lijekova u vrijednosti barem milijun > HRK godišnje, pa još uzmemo u račun od novinara spominjanih > 12%, farmaceutske nam kuće duguju barem 2-3 apartmana na moru ( čak i ako > odbijemo kemijske, ručnike, ruksake i kotizacije za kongrese OM- imamo ih > čak četiri godišnje, što jasno ukazuje da nam je samo od farmaceutskih > tvrtki plaćeni nerad na pameti). > > Još nešto, gdje su u toj koruptivnoj priči magistre/i farmacije? Novinari > ili misle da one/i ne igraju tu nikakvu ulogu, ili ih drže prvenstveno > trgovcima kojima razni rabati i nagradna putovanja spadaju u opis radnog > mjesta. > > Pitanje za medije: Ako nas neka generička firma (takve uglavnom surađuju s > OM) plaćanjem nekog od kongresa OM motivira na propisivanje njihovih > lijekova koji su najjeftiniji među paralelama, i na taj način smanjimo > HZZ-u troškove za desetak posto, je li to baš takav sukob interesa zbog > kojega smo zaslužili stup srama? > > Mislim da bi u ovom trenutku mi kao obiteljski liječnici trebali odigrati > proaktivan potez prema farmaceustkim tvrtkama, a zašto ne i prema > HZZO-u, sa zahtjevom da većinu stručnih predavanja za obiteljske drže > obiteljski liječnici, uz honorar daleko niži od bolničkih kolega, a razliku > bi farmaceutske kuće mogle transparentno uložiti u fond za opremanje > ambulanti. Time bi javnosti pokazali da nam je temeljni cilj pružanje što > kvalitetnije usluge svojim pacijentima, a jedini način "bogaćenja" bio bi > preko DTP postupaka (delimitiranih) koje bi odrađivali uz pomoć te opreme > (koja može biti i u vlasništvu HZZO-a, da je slučajno ne bi preprodavali na > "crnom" tržištu). > > > Pozdrav, Saša > > > > > > > *From:* Leonardo Bressan <ordinacija.dr.leonardo.bressan@xxxxxxxxx> > *To:* smartdoctor@xxxxxxxxxxxxx > *Sent:* Friday, August 10, 2012 8:48 AM > *Subject:* [smartdoctor] Afera Pfizer > SEC Charges Pfizer with FCPA Violations > *FOR IMMEDIATE RELEASE > 2012-152* > *Washington, D.C., Aug. 7, 2012** – *The Securities and Exchange > Commission today charged Pfizer Inc. with violating the Foreign Corrupt > Practices Act (FCPA) when its subsidiaries bribed doctors and other health > care professionals employed by foreign governments in order to win business. > The SEC alleges that employees and agents of Pfizer’s subsidiaries in > Bulgaria, China, Croatia, Czech Republic, Italy, Kazakhstan, Russia, and > Serbia made improper payments to foreign officials to obtain regulatory and > formulary approvals, sales, and increased prescriptions for the company’s > pharmaceutical products. They tried to conceal the bribery by improperly > recording the transactions in accounting records as legitimate expenses for > promotional activities, marketing, training, travel and entertainment, > clinical trials, freight, conferences, and advertising. > Additional Materials > > - SEC Complaint Against > Pfizer<http://www.sec.gov/litigation/complaints/2012/comp-pr2012-152-pfizer.pdf> > - SEC Complaint Against > Wyeth<http://www.sec.gov/litigation/complaints/2012/comp-pr2012-152-wyeth.pdf> > - More SEC FCPA Cases<http://www.sec.gov/spotlight/fcpa/fcpa-cases.shtml> > > The SEC separately charged another pharmaceutical company that Pfizer > acquired a few years ago – Wyeth LLC – with its own FCPA violations. Pfizer > and Wyeth agreed to separate settlements in which they will pay more than > $45 million combined to settle their respective charges. In a parallel > action, the Department of Justice announced that Pfizer H.C.P. Corporation > agreed to pay a $15 million penalty to resolve its investigation of FCPA > violations. > “Pfizer subsidiaries in several countries had bribery so entwined in their > sales culture that they offered points and bonus programs to improperly > reward foreign officials who proved to be their best customers,” said Kara > Brockmeyer, Chief of the SEC Enforcement Division’s Foreign Corrupt > Practices Act Unit. “These charges illustrate the pitfalls that exist for > companies that fail to appropriately monitor potential risks in their > global operations.” > According to the SEC’s complaint against Pfizer filed in U.S. District > Court for the District of Columbia, the misconduct dates back as far as > 2001. Employees of Pfizer’s subsidiaries authorized and made cash payments > and provided other incentives to bribe government doctors to utilize Pfizer > products. In China, for example, Pfizer employees invited “high-prescribing > doctors” in the Chinese government to club-like meetings that included > extensive recreational and entertainment activities to reward doctors’ past > product sales or prescriptions. Pfizer China also created various “point > programs” under which government doctors could accumulate points based on > the number of Pfizer prescriptions they wrote. The points were redeemed for > various gifts ranging from medical books to cell phones, tea sets, and > reading glasses. In Croatia, Pfizer employees created a “bonus program” for > Croatian doctors who were employed in senior positions in Croatian > government health care institutions. Once a doctor agreed to use Pfizer > products, a percentage of the value purchased by a doctor’s institution > would be funneled back to the doctor in the form of cash, international > travel, or free products. > According to the SEC’s complaint, Pfizer made an initial voluntary > disclosure of misconduct by its subsidiaries to the SEC and Department of > Justice in October 2004, and fully cooperated with SEC investigators. > Pfizer took such extensive remedial actions as undertaking a comprehensive > worldwide review of its compliance program. > The SEC further alleges that Wyeth subsidiaries engaged in FCPA violations > primarily before but also after the company’s acquisition by Pfizer in late > 2009. Starting at least in 2005, subsidiaries marketing Wyeth nutritional > products in China, Indonesia, and Pakistan bribed government doctors to > recommend their products to patients by making cash payments or in some > cases providing BlackBerrys and cell phones or travel incentives. They > often used fictitious invoices to conceal the true nature of the payments. > In Saudi Arabia, Wyeth’s subsidiary made an improper cash payment to a > customs official to secure the release of a shipment of promotional items > used for marketing purposes. The promotional items were held in port > because Wyeth Saudi Arabia had failed to secure a required Saudi Arabian > Standards Organization Certificate of Conformity. > Following Pfizer’s acquisition of Wyeth, Pfizer undertook a risk-based > FCPA due diligence review of Wyeth’s global operations and voluntarily > reported the findings to the SEC staff. Pfizer diligently and promptly > integrated Wyeth’s legacy operations into its compliance program and > cooperated fully with SEC investigators. > In settling the SEC’s charges, Wyeth neither admitted nor denied the > allegations. Pfizer consented to the entry of a final judgment ordering it > to pay disgorgement of $16,032,676 in net profits and prejudgment interest > of $10,307,268 for a total of $26,339,944. Wyeth also is required to report > to the SEC on the status of its remediation and implementation of > compliance measures over a two-year period, and is permanently enjoined > from further violations of Sections 13(b)(2)(A) and 13(b)(2)(B) of the > Securities Exchange Act of 1934. Wyeth consented to the entry of a final > judgment ordering it to pay disgorgement of $17,217,831 in net profits and > prejudgment interest of $1,658,793, for a total of $18,876,624. As a Pfizer > subsidiary, the status of Wyeth’s remediation and implementation of > compliance measures will be subsumed in Pfizer’s two-year self-reporting > period. Wyeth also is permanently enjoined from further violations of > Sections 13(b)(2)(A) and 13(b)(2)(B) of the Exchange Act. The settlements > are subject to court approval. > The SEC’s investigation was conducted by Michael Catoe and Charles Cain of > the Enforcement Division’s FCPA Unit. The SEC acknowledges the assistance > of the U.S. Department of Justice’s Criminal Division’s Fraud Section and > the Federal Bureau of Investigation in this matter. > # # # > *http://www.sec.gov/news/press/2012/2012-152.htm* > ****__________ NOD32 2604 (20071019) Informacija __________****Ova je > poruka provjerena NOD32 antivirusnim sistemom.**http://www.nod32.com.hr/** > **** >